Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

FDA announces supplement recall over risk of heart attack or stroke
Silintan is a dietary supplement marketed as a treatment for joint and body aches. According to a recent analysis by the FDA, however, all lots contained undeclared meloxicam, creating an increased risk of adverse events.
Drugmaker moves ahead with sublingual heart attack treatment after positive FDA meeting
Based on feedback from the FDA, Aspire Biopharma plans on completing a multicenter clinical trial and then seeking regulatory approval for its new high-dose sublingual aspirin therapy.
CBD shows early potential to treat heart disease
Early evidence suggests CBD could help clinicians treat pericarditis, myocarditis and other significant heart conditions. Additional research is still required, however, including many more clinical trials.
Bleeding reversal agent pulled from market over FDA’s safety concerns
AstraZeneca has stopped selling Andexxa because randomized data suggested some patients may face an increased risk of certain adverse events. The company emphasized that it remains confident in the agent's abilities.
FDA approves new drug for genetic heart disease
Cytokinetics has secured FDA approval for aficamten, its new drug for the treatment of symptomatic obstructive HCM. Aficamten will be sold under the brand name Myqorzo.

Tafamidis shows promise for treating cardiac amyloidosis

Research presented this week at the European Society of Cardiology Congress in Munich suggests a new treatment may be emerging for transthyretin amyloid cardiomyopathy—a condition previously thought to be rare and untreatable.

Eidos Therapeutics Initiates Phase 2 Clinical Trial for AG10 Targeting Transthyretin Amyloidosis Cardiomyopathy

SAN FRANCISCO, May 3, 2018 /PRNewswire/ — Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), today announced dosing of the first patient in the Phase 2 clinical trial of AG10 in patients with ATTR cardiomyopathy.

Pharmaceutics

FDA announces supplement recall over risk of heart attack or stroke

Drugmaker moves ahead with sublingual heart attack treatment after positive FDA meeting

CBD shows early potential to treat heart disease

Bleeding reversal agent pulled from market over FDA’s safety concerns

FDA approves new drug for genetic heart disease